Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.
Read more from the original source:
GENFIT Announces 2024 Financial Calendar
Basel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer.7 Until now, Tecentriq has been given directly into patients’ veins by IV infusion which takes approximately 30-60 minutes.6 The new subcutaneous injection will cut treatment time to approximately seven minutes, with most injections taking between four and eight minutes.6 The marketing authorisation applies to all approved indications of Tecentriq IV.7
Read the rest here:
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
DUBLIN, Jan. 10, 2024 /PRNewswire/ --The"Induced Pluripotent Stem Cells: Global Markets 2023-2028" report has been added toResearchAndMarkets.com's offering.
This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types.
Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.
This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.
This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market's growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028.
One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.
The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.
The Report Includes
Companies Profiled
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Chapter 4 Market Dynamics
Chapter 5 Induced Pluripotent Stem Cell Applications
Chapter 6 Induced Pluripotent Stem Cell Market Segmentation and Forecast
Chapter 7 Induced Pluripotent Stem Cells Research Application Market
Chapter 8 Induced Pluripotent Stem Cell Contract Service Market
Chapter 9 Clinical Application Market Trend Analysis
Chapter 10 Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/r/i3vsaw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
Read more here:
Induced Pluripotent Stem Cells Global Market Report 2023-2028 - Key Market Drivers Include Use of iPSCs in ... - PR Newswire
In a groundbreaking revelation, the Global Cell Line Development Industry is poised for an extraordinary surge, with sales projected to reach an impressive US$10.6 billion by 2033, propelled by a robust Compound Annual Growth Rate (CAGR) of 7.7% from 2023. These findings, based on a comprehensive analysis by Future Market Insights (FMI), reveal a significant leap from the estimated US$4.7 billion valuation in 2022.
The driving force behind this unprecedented growth is the escalating adoption of bio-therapeutics for the treatment of chronic diseases such as arthritis, diabetes, and cancer. As the demand for innovative therapeutic solutions continues to rise, the Global Cell Line Development Industry is witnessing an increased need for automated cell line development and specialized cell line development services.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-7566
The rapid increase in the prevalence of cancer and neurology disorders and the lack of efficient treatment solutions for these diseases have created the need for more advanced and efficient treatment pathways. Companies and government organizations are investing in research and development activities and are also focusing more on cell line development in search of new cellular pathways to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide a boost to the Global Cell Line Development Industry.
In recent times contract research organizations have focused on cell line development and cell line research activities. According to the National Institutes of Health (NIH), the estimated total federal spending on all types of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, the government is supporting cell line development through national funding agencies like the Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the Department of Science and Technology (DST).
Regenerative medicines are the next-generation treatment solution and Cell Line Development or Cell Culture is a vital part of regenerative medicine. Increasing demand for regenerative medicines in cancer treatment would positively impact the growth of the Global Cell Line Development Industry over the forecast period.
The biopharmaceutical companies operating in the development of novel drug lines are expected to hold promising revenue opportunities in the Global Cell Line Development Industry.
Future Market Insights (FMI) has segmented the Global Cell Line Development Industry based on product type, cell line source type, end user, type of cell line, and region.
Product type segment in the Global Cell Line Development Industry is segmented into media and reagents, equipment, and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. The reagent and media segment in the cell line development market is expected to witness noteworthy growth in terms of revenue owing to a rapid increase in demand for cell culture and cell-based assays.
Global Cell Line Development Industry by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipated to witness significant growth in the overall Global Cell Line Development Industry. This growth of the mammalian cells segment in the cell line development market is driven by increased production of biologics drugs that require mammalian cells. Increasing antibody production is the major driving factor behind the growth of the mammalian cell lines segment in the Global Cell Line Development Industry.
Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gauchers disease, is a genetic disorder characterized by a lack of -glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produced in mammalian cell lines. Mammalian cell lines are also useful in the production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease-causing agents in the body. For example Under the cell line type segment in the Global Cell Line Development Industry, recombinant cell line development is the most demanding type of cell line due to its large application in biologics production, protein interaction, gene activation, toxicity testing, and drug screening.
Request Your Customized Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-7566
Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period
North American and European cell line development markets will dominate owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to the increased number of research organizations engaged in novel biologics and biosimilars fastest revenue growth in the overall cell line development market.
The Asia Pacific region in the Cell line development market is anticipated to witness increasing demand for biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.
FMIs report tracks some of the key companies operating in the Global Cell Line Development Industry, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.
Key Segments:
By Source Type:
By End User:
By Cell Lines:
Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-7566
Author
Sabyasachi Ghosh(Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA T: +1-845-579-5705 For Sales Enquiries:sales@futuremarketinsights.com Website:https://www.futuremarketinsights.com LinkedIn|Twitter|Blogs|YouTube
See original here:
Global Cell Line Development Industry on Track for a US$10.6 Billion Boom by 2033, Fuelled by 7.7% CAGR | FMI ... - Market Research Blog
Led by Octopus Ventures, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, this funding marks the first stage in commercialising CellVoyant's AI and imaging platforms.
The company aims to enable the cost-effective and rapid development of novel cell therapies. The proceeds from this funding round will be used to increase headcount, expand laboratory and experimental infrastructure, and support R&D.
Rafael E. Carazo Salas, CEO and founder of CellVoyant, said: Cell therapies have the potential to revolutionise the way we treat diseases that affect millions of people every year. By combining the latest advances in AI and live cell imaging, we can help bring these transformative treatments to the market quickly, reliably, and cost-effectively. Todays milestone validates the potential of our approach and will help us to accelerate our R&D capabilities.
Stem cells unlock a range of treatment possibilities that have not previously been available to patients. Current treatment options act on the bodys existing cells, while stem cells can develop into many different cell types in the body - regenerating damaged tissues and organs or replacing dysfunctional and dead cells.
There are already promising potential applications in chronic diseases, such as cancer, and metabolic diseases like diabetes and age-related macular degeneration. In future, stem cells could be used to alleviate currently untreatable conditions like dementia, fertility, and spinal cord injury.
Stem cell biology is complex and unpredictable, and producing pure, viable populations of stem cell derivatives at clinical scale can be slow and challenging.
In fact, 84% of cell therapy assets fail within two years of development, and 47% of cell therapy assets still fail after the five-year point in development.
CellVoyants platform combines advanced AI with live cell imaging to address these concerns.
Its technology can extract spatial and temporal information in real-time from hundreds of millions of cells within complex cell mixtures, helping scientists understand their composition and forecast how they will evolve.
This allows them to forecast stem cell behaviour with unprecedented precision and find optimal pathways for differentiating cells into specific cell types, such as nerve, cardiac or blood, facilitating more effective development of cell therapies.
According to the company, its technology can improve target cell yields, reduce time, and can offer potential savings of $10 100 million per therapy.
Uzma Choudry, Lead Biotech Investor at Octopus Ventures, added: University spin-outs like CellVoyant are at the heart of the UKs thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments.
Originally posted here:
CellVoyant secures 7.6 million seed funding to develop stem cell therapies with AI - BioPharma-Reporter.com
One of the biggest barriers to regenerative medicine is immunological rejection by the recipient, a problem researchers at the University of Arizona Health Sciences are one step closer to solving after genetically modifying pluripotent stem cells to evade immune recognition. The study Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers waspublished in Stem Cell Reports today.
Pluripotent stem cells can turn into any type of cell in the body. The findings offer a viable path forward for pluripotent stem cell-based therapies to restore tissues that are lost in diseases such as Type 1 diabetes or macular degeneration.
There has been a lot of excitement for decades around the field of pluripotent stem cells and regenerative medicine, said principal investigator Deepta Bhattacharya, PhD, a professor in the UArizona College of Medicine Tucsons Department of Immunobiology. What we have learned from the experiences of organ transplantation is that you have to have matched donors, but the person receiving the transplant often still requires lifelong immune suppression, and that means there is increased susceptibility to infections and cancer. Weve been trying to figure out what it is that you need to do to those stem cells to keep them from getting rejected, and it looks like we have a possible solution.
To test their hypothesis, Bhattacharya and the research team used CRISPR-Cas9 technology, genetic scissors that allow scientists to make precise mutations within the genome at extremely specific locations.
Using human pluripotent stem cells, the team located the specific genes they believed were involved in immune rejection and removed them. Prior research into pluripotent stem cells and immune rejection looked at different parts of the immune system in isolation. Bhattacharya and his colleagues from The New York Stem Cell Foundation Research Institute, St. Jude Childrens Research Hospital and the Washington University School of Medicine opted to test their genetically modified stem cells in a complete and functional immune system.
The immune system is really complicated and there are all sorts of ways it can recognize and reject things, said Bhattacharya, a member of the UArizona Cancer Center and the BIO5 Institute who also serves on the UArizona Health Sciences Center for Advanced Molecular and Immunological Therapies advisory council.
Transplantation across species, across the xenogeneic barrier, is difficult and is a very high bar for transplantation. We decided if we could overcome that barrier, then we could start to have confidence that we can overcome what should be a simpler human-to-human barrier, and so thats basically what we did.
The research team tested the modified stem cells by placing them into mice with normal, fully functioning immune systems. The results were promising the genetically engineered pluripotent stem cells were integrated and persisted without being rejected.
That has been the holy grail for a while. You might actually have a chance of being able to perform pluripotent stem cell-based transplants without immune suppressing the person who is receiving them. That would be an important advance, both clinically and from the simple standpoint of scale, Bhattacharya said. You wouldnt have to make individualized therapies for every single person you can start with one pluripotent stem cell type, turn it into the cell type you want and then give it to almost anyone.
The next steps, Bhattacharya said, include testing the genetically modified pluripotent stem cells in specific disease models. He is already working with collaborators at The New York Stem Cell Foundation and the Juvenile Diabetes Research Foundation to test the technology in animal models for Type 1 diabetes.
We needed to overcome the immune system first. The next steps are how do we use these cells? Bhattacharya said. We set the bar pretty high for our study and the fact that we were successful gives us some confidence that this can really work.
Bhattacharya also is the co-founder of startup Clade Therapeutics in Boston, which licensed the technology through Tech Launch Arizona, the University of Arizonas commercialization arm. Clade Therapeutics is establishing a robust cellular platform using stem cell-derived immune cells for the treatment of cancer and autoimmune diseases. The company said it hopes to begin clinical trials by the end of the year.
Co-authors on the paper include: Hannah Pizzato, PhD, research specialist in the College of Medicine Tucsons Department of Immunobiology; Paula Alonso-Guallart, DVM, PhD, James Woods and Frederick J. Monsma Jr., PhD, of The New York Stem Cell Foundation Research Institute; Jon P. Connelly, PhD, and Shondra M. Pruett-Miller, PhD, of the St. Jude Childrens Research Hospital; and Todd A. Fehniger, MD, PhD, and John P. Atkinson, MD, of the Washington University School of Medicine.
Read this article:
Researchers genetically modify stem cells to evade immunological rejection - University of Arizona
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- In 2023Cell therapy technologiesmarket were valued at USD 5.5 billion in 2023 with significant growth and are projected to reach USD 47.3 billion by 2033 with an outstanding CAGR of 24.7%.
The surge in demand for advanced diagnostic tools and therapeutic interventions is pushing the cell therapy technology market forward. Cell therapy, a main element in treating regenerative medicines, has become extensively popular, particularly in regenerative medicine. Combined with other equipment like Platelet-Rich plasma (PRP), cell therapy improves its power and effectiveness, proposing extra benefits to patients.
Get additional highlights on major revenue-generating segments, Request a Cell Therapy Technologies Market sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/
Cell therapy comprises launching innovative, healthy cells into a patient's body, playing a vital role in handling certain cancers and neurological diseases such as Parkinson's, amyotrophic lateral sclerosis (ALS), and diabetes. With over 1 million individuals worldwide suffering from Parkinson's disease, a number projected to reach 1.2 million by 2030, cell therapy emerges as a promising solution. Likewise, ALS is predominant, mostly in Western Europe, where it has a prevalence rate of 9.62 per 1,000,000 populations.
The benefits of cell therapy technologies comprise pain reduction, augmented functionality, fast-tracked recovery, aid in complex injuries, and a reduced risk of nerve damage and communicable diseases. As these therapies display innovative diagnostic and treatment methods, the market is poised for rapid expansion to meet the cumulative requirement for transformative medical solutions during the forecasted period.
Key Takeaways
Driving Factors
Introduction of Innovative Products
These innovative products, crafted to meet the requirements of different patients, have been instrumental in the advancement of cell therapies. This trend of continual product innovation is essential for keeping pace with the evolving demands of healthcare, ensuring the market's resilience and adaptability. The focus on innovation drives market growth by providing more effective, efficient, and tailored treatment options, thereby enhancing patient outcomes and expanding the potential applications of cell therapies. The market is composed of unrelenting growth, reinforced by a pipeline of advanced transformative cell therapy technologies.
Enhanced Demographic and Environmental Dynamics
Population growth escalates the demand for innovative healthcare solutions, including cell therapies for diverse medical conditions. Climate change, influencing disease patterns and health vulnerabilities, further propels the need for advanced treatments. These key factors collectively drive the development and adoption of cell therapy technologies, as they offer targeted and efficient treatment options for an array of health issues emerging in this changing global landscape.
To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://marketresearch.biz/report/cell-therapy-technologies-market/#inquiry
Restraining Factors
Cost and Reimbursement Issues
Cell therapy treatments are typically associated with high costs, both in terms of production and administration. The problem of reimbursement and costs is crucial to the development of the cell-based therapy business. Furthermore, the lack of clear reimbursement pathways adds to the complexity as insurers grapple with how to classify and cover these novel treatments. This makes them financially out of reach for many patients and healthcare systems. These financial hurdles not only limit patient access but also deter investment and innovation in the field, as developers and benefactors face vagueness about the return on their significant funds in these advanced therapies.
Growth Opportunities
Increased Interest in customized medicines
Personalized medicine's approach of tailoring treatments to individual patients aligns perfectly with the capabilities of cell therapies. These therapies' adaptability to patient-specific needs positions them at the forefront of innovative treatments for a variety of medical conditions. This illustrates the growing significance of technology in the realm of personalized healthcare in the upcoming era of cell therapy. As healthcare continues to evolve towards more personalized strategies, the demand for cell therapy technologies is expected to rise, bolstered by their potential to provide targeted, patient-specific treatments.
Have Queries? Speak to an expert or To Download/Request a Sample, Click here.
Regional Analysis
North America rules the cell therapy technologies market, holding 55.60% due to robust research infrastructure, substantial biotech investments, and favorable policies. The U.S. leads with ground-breaking biotech firms and supportive government initiatives. Europe, compelled by research and regulatory support, sees contributions from Germany, the UK, and France. In Asia-Pacific, prompt market growth results from augmented healthcare investments and biomedical research, particularly in Japan and South Korea. The region's large population and rising chronic diseases present substantial opportunities for expanding cell therapy technologies.
Segment Analysis
By therapy type, Autologous therapies rule the market segment due to their substantial role in treatments utilizing cells. This method is widely used in various treatments, including certain types of cancer therapies, where patients' cells are engineered to fight cancer cells more effectively. Through the use of donors' cells, allogeneic therapies can play a significant role in treatments utilizing cells. The most significant benefit of autologous treatment is that there is less possibility that the immune system will reject it and related complications since the cells are derived from patients themselves. These therapies have the advantage of being available off-the-shelf, making them more accessible and sometimes more cost-effective.
By cell type, stem cells dominate the market segment due to their extensive use in hematopoietic stem cell transplantation for blood and bone marrow disorders. Stem cells ability to differentiate into various cell types makes them incredibly valuable in regenerative medicine and the treatment of various diseases. Adipose-derived stem cells are being explored for their potential in regenerative therapies due to their abundance and ease of extraction. Non-stem cell therapies, while not as adaptable as stem cells, are important in precise therapeutic applications, predominantly in certain types of cancer treatments where immune cells are contrived to target cancer cells.
By cell therapy therapeutic area type, oncology leads the market segment due to the effectiveness of cell therapy in treating various types of cancers, particularly through approaches like CAR-T cell therapies, which have transformed cancer treatment. These therapies have shown remarkable results in certain types of blood cancer, leading to significant investment and research in expanding their application to other cancer types. In dermatology, cell therapies offer advanced treatment options for skin regeneration and healing. Other therapeutic areas like cardiovascular disease (CVD), musculoskeletal disorders, dermatology, and others are also significant. Cell therapies in CVD aim to regenerate damaged heart tissue, while in musculoskeletal disorders, they are used for tissue repair and pain management.
For more insights on the historical and Forecast market data from 2016 to 2033 - download a sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/
Segments Covered in this Report
By Therapy Type
By Cell Type
By Cell Therapy Therapeutic Area
By Geography
Grow your profit margin with Marketresearch.biz - Purchase This Premium Report at https://marketresearch.biz/purchase-report/?report_id=8948
Competitive Landscape Analysis
In the dynamic field of cell therapy technologies, industry front-runners such as Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson & Company, Merck KGaA, Lonza Group, Sartorius AG, FUJIFILM Irvine Scientific, and Avantor, Inc. play pivotal roles. Their inclusive product ranges and tactical focuses on innovation, accuracy, and amalgamation contribute significantly to advancing cell therapy research, manufacturing, and efficiency.
Key Market Players
Recent Developments
Browse More Related Reports
About Us:
MarketResearch.Biz (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm.MarketResearch.Bizprovides customization to suit any specific or unique requirement and tailor-made reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.
Follow Us on LinkedIn:https://www.linkedin.com/company/marketresearch-biz/ Follow Us on Facebook:https://www.facebook.com/marketresearch.biz Follow Us on Twitter:https://twitter.com/PrudourResearch
Here is the original post:
Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 ... - GlobeNewswire
KENNEDY SPACE CENTER (FL), January 10, 2024 More than two dozen investigations sponsored by the International Space Station (ISS) National Laboratory, many of which focus on the life sciences, will fly on Axiom Spaces third private astronaut mission to the orbiting laboratory. Axiom Mission 3 (Ax-3) aims to help expand a new era of privatized utilization of the space station that will bring value to humanity while enabling the development of a robust and sustainable market in low Earth orbit (LEO) by advancing research in microgravity.
Four astronauts are slated to launch on a SpaceX Falcon 9 rocket and Dragon spacecraft to the space station no earlier than Wednesday, January 17, at 5:11 p.m. EST from NASAs Kennedy Space Center in Florida. During a planned two-week mission, Axiom Spaces chief astronaut and former NASA astronaut Michael Lpez-Alegra (commander), Walter Villadei of Italy (pilot), Alper Gezeravc of Trkiye (mission specialist), and European Space Agency (ESA) project astronaut Marcus Wandt of Sweden (mission specialist) will conduct more than 30 experiments.
Building on years of foundational research performed in microgravity, a number of these investigations aim to utilize the unique LEO environment to better understand an array of biological processes, including how spaceflight affects the human body, the mechanisms behind certain diseases, and how stem cell research can help lead to the development of novel therapeutics.
Below are some highlights of the investigations launching on the Ax-3 mission:
Through these private astronaut missions, Axiom Space and the ISS National Lab partner to expand access to the unique microgravity environment for the benefit of humanity. Ax-3 represents the first all-European commercial mission to the space station, further expanding spaceflight opportunities to more countries, companies, and people. In addition to the projects highlighted above, Ax-3 includes a strong focus on the scientific portfolios of the European nations represented on this mission, seeking to enhance scientific knowledge gained for humanity.
Read more about these investigations and others launching on this mission in Axiom Spaces Research Overview and on the ISS National Lab Ax-3 launch page.
Download the high-resolution image for this release: Axiom-2 Launch
Media Contact: Patrick ONeill 904-806-0035 PONeill@ISSNationalLab.org
# # #
About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space (CASIS) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.
As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.
About Axiom Space: Axiom Space is building for beyond, guided by the vision of a thriving home in space that benefits every human, everywhere. The leading provider of human spaceflight services and developer of human-rated space infrastructure, Axiom Space operates end-to-end missions to the International Space Station today while developing its successor, Axiom Station the worlds first commercial space station in low-Earth orbit, which will sustain human growth off the planet and bring untold benefits back home. For more information visit Axiom Spaces website.
Read the original post:
Life Science Research Heads to the ISS on Axiom Mission 3 - ISS National Lab
